Sign up Australia
Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers Ltd to promote proprietary glaucoma surgery

Ellex Medical Lasers Ltd to promote proprietary glaucoma surgery

Ellex Medical Lasers Ltd (ASX:ELX) will present a positive 12-month case series data for the company’s proprietary ABiC minimally invasive glaucoma surgery (MIGS) procedure at the American Society of Cataract and Refractive Surgery meeting in New Orleans, U.S.A.

Ellex manufactures lasers and other medical devices for the diagnosis and treatment of eye disease.

The results from the case series study show that ABiC can effectively reduce intraocular pressure (IOP or fluid pressure inside the eye) and medication dependence in glaucoma patients with minimal complications.

The case series study, which was undertaken in the U.S., included 228 eyes with mild-to-moderate glaucoma who underwent ABiC either alone or in combination with cataract surgery.

Encouragingly, in 98 patients who underwent ABiC as a standalone procedure, there was an average decrease of 36.74% in IOP and 66.66% in medications.

Data for the entire patient cohort showed a total average decrease of 30% in IOP and a 50% reduction in medications, 12 months after the ABiC surgery.

The company had developed ABiC to address the shortcomings of conventional glaucoma treatment options, which includes chronic use of daily multi-dose topical glaucoma medications.

Since launching ABiC into the fast-growing MIGS market, Ellex has achieved sales growth in the U.S of 25% during the 9 months to 31 March 2016, compared with the prior corresponding period.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

Newswire
November 30 2016

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use